Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients

Accumulating studies have investigated the prognostic and clinical significance of programmed death ligand-1 (PD-L1) expression in patients with hepatocellular carcinoma (HCC); however, the results were conflicting and inconclusive. We conducted a meta-analysis to combine controversial data to preci...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2016-01, Vol.9, p.4805-4813
Main Authors: Gu, Xiaobin, Gao, Xian-Shu, Xiong, Wei, Guo, Wei, Han, Linjun, Bai, Yun, Peng, Chuan, Cui, Ming, Xie, Mu
Format: Article
Language:English
Subjects:
Apoptosis
Brain cancer
Confidence intervals
Infections
Ligands
Liver cancer
Medical prognosis
Meta-analysis
Original Research
PD-L1 protein
Systematic review
Tumors
Viral infections
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c521t-2ee1f1ec6092c06cf9c38d3429cfca4dd5ce30ed1910dd6751d4a5c9164c67dc3
cites
container_end_page 4813
container_issue
container_start_page 4805
container_title OncoTargets and therapy
container_volume 9
creator Gu, Xiaobin
Gao, Xian-Shu
Xiong, Wei
Guo, Wei
Han, Linjun
Bai, Yun
Peng, Chuan
Cui, Ming
Xie, Mu
description Accumulating studies have investigated the prognostic and clinical significance of programmed death ligand-1 (PD-L1) expression in patients with hepatocellular carcinoma (HCC); however, the results were conflicting and inconclusive. We conducted a meta-analysis to combine controversial data to precisely evaluate this issue. Relevant studies were thoroughly searched on PubMed, Web of Science, and Embase until April 2016. Eligible studies were evaluated by selection criteria. Hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the prognostic role of PD-L1 for overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS). Odds ratio (OR) with 95% CI were selected to assess the relationship between PD-L1 and clinicopathological features of HCC patients. Publication bias was tested using Begg's funnel plot. A total of seven studies published from 2009 to 2016 were included for meta-analysis. The data showed that high PD-L1 expression was correlated to shorter OS (HR =2.09, 95% CI: 1.66-2.64, P
doi_str_mv 10.2147/OTT.S110713
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4976917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2242720837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-2ee1f1ec6092c06cf9c38d3429cfca4dd5ce30ed1910dd6751d4a5c9164c67dc3</originalsourceid><addsrcrecordid>eNpdkc9rFTEQx4Mo9oeevMuCF0G2ZpJssrkIUrQWCj30eQ5xkn0vdTdZk13R_9689lmqpwyZz3xnvnwJeQX0jIFQ7683m7MbAKqAPyHHAKpvpeb06aP6iJyUckuplD0Tz8kRUx2XIMQx-X4ZMXtbvGvmnLbZTlMtnbfLrhnD1kbXQuN_zdmXElKskHcBl9LMKeW7kZhKKE2Izc7Pdknox3EdbW7QZgwxTbap38HHpbwgzwY7Fv_y8J6Sr58_bc6_tFfXF5fnH69a7BgsLfMeBvAoqWZIJQ4aee-4YBoHtMK5Dj2n3oEG6pxUHThhO9QgBUrlkJ-SD_e68_qtusG6O9vRzDlMNv82yQbzbyeGndmmn0ZoJTWoKvD2IJDTj9WXxUyh7I3Z6NNaDPTAek2Z7ir65j_0Nq05VnuGMcEUoz3fC767pzCnUrIfHo4BavYhmhqiOYRY6deP739g_6bG_wAdrpra</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242720837</pqid></control><display><type>article</type><title>Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients</title><source>Taylor &amp; Francis (Open Access)</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Gu, Xiaobin ; Gao, Xian-Shu ; Xiong, Wei ; Guo, Wei ; Han, Linjun ; Bai, Yun ; Peng, Chuan ; Cui, Ming ; Xie, Mu</creator><creatorcontrib>Gu, Xiaobin ; Gao, Xian-Shu ; Xiong, Wei ; Guo, Wei ; Han, Linjun ; Bai, Yun ; Peng, Chuan ; Cui, Ming ; Xie, Mu</creatorcontrib><description>Accumulating studies have investigated the prognostic and clinical significance of programmed death ligand-1 (PD-L1) expression in patients with hepatocellular carcinoma (HCC); however, the results were conflicting and inconclusive. We conducted a meta-analysis to combine controversial data to precisely evaluate this issue. Relevant studies were thoroughly searched on PubMed, Web of Science, and Embase until April 2016. Eligible studies were evaluated by selection criteria. Hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the prognostic role of PD-L1 for overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS). Odds ratio (OR) with 95% CI were selected to assess the relationship between PD-L1 and clinicopathological features of HCC patients. Publication bias was tested using Begg's funnel plot. A total of seven studies published from 2009 to 2016 were included for meta-analysis. The data showed that high PD-L1 expression was correlated to shorter OS (HR =2.09, 95% CI: 1.66-2.64, P&lt;0.001) as well as poor DFS/RFS (HR =2.3, 95% CI: 1.46-3.62, P&lt;0.001). In addition, increased PD-L1 expression was also associated with tumor differentiation (HR =1.51, 95% CI: 1-2.29, P=0.05), vascular invasion (HR =2.16, 95% CI: 1.43-3.27, P&lt;0.001), and α-fetoprotein (AFP; HR =1.46, 95% CI: 1-2.14, P=0.05), but had no association with tumor stage, tumor size, hepatitis history, sex, age, or tumor multiplicity. No publication bias was found for all analyses. This meta-analysis revealed that overexpression of PD-L1 was predictive for shortened OS and DFS/RFS in HCC. Furthermore, increased PD-L1 expression was associated with less differentiation, vascular invasion, and AFP elevation.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S110713</identifier><identifier>PMID: 27536144</identifier><language>eng</language><publisher>New Zealand: Taylor &amp; Francis Ltd</publisher><subject>Apoptosis ; Brain cancer ; Confidence intervals ; Infections ; Ligands ; Liver cancer ; Medical prognosis ; Meta-analysis ; Original Research ; PD-L1 protein ; Systematic review ; Tumors ; Viral infections</subject><ispartof>OncoTargets and therapy, 2016-01, Vol.9, p.4805-4813</ispartof><rights>2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Gu et al. This work is published and licensed by Dove Medical Press Limited 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-2ee1f1ec6092c06cf9c38d3429cfca4dd5ce30ed1910dd6751d4a5c9164c67dc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2242720837/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2242720837?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27536144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Xiaobin</creatorcontrib><creatorcontrib>Gao, Xian-Shu</creatorcontrib><creatorcontrib>Xiong, Wei</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><creatorcontrib>Han, Linjun</creatorcontrib><creatorcontrib>Bai, Yun</creatorcontrib><creatorcontrib>Peng, Chuan</creatorcontrib><creatorcontrib>Cui, Ming</creatorcontrib><creatorcontrib>Xie, Mu</creatorcontrib><title>Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Accumulating studies have investigated the prognostic and clinical significance of programmed death ligand-1 (PD-L1) expression in patients with hepatocellular carcinoma (HCC); however, the results were conflicting and inconclusive. We conducted a meta-analysis to combine controversial data to precisely evaluate this issue. Relevant studies were thoroughly searched on PubMed, Web of Science, and Embase until April 2016. Eligible studies were evaluated by selection criteria. Hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the prognostic role of PD-L1 for overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS). Odds ratio (OR) with 95% CI were selected to assess the relationship between PD-L1 and clinicopathological features of HCC patients. Publication bias was tested using Begg's funnel plot. A total of seven studies published from 2009 to 2016 were included for meta-analysis. The data showed that high PD-L1 expression was correlated to shorter OS (HR =2.09, 95% CI: 1.66-2.64, P&lt;0.001) as well as poor DFS/RFS (HR =2.3, 95% CI: 1.46-3.62, P&lt;0.001). In addition, increased PD-L1 expression was also associated with tumor differentiation (HR =1.51, 95% CI: 1-2.29, P=0.05), vascular invasion (HR =2.16, 95% CI: 1.43-3.27, P&lt;0.001), and α-fetoprotein (AFP; HR =1.46, 95% CI: 1-2.14, P=0.05), but had no association with tumor stage, tumor size, hepatitis history, sex, age, or tumor multiplicity. No publication bias was found for all analyses. This meta-analysis revealed that overexpression of PD-L1 was predictive for shortened OS and DFS/RFS in HCC. Furthermore, increased PD-L1 expression was associated with less differentiation, vascular invasion, and AFP elevation.</description><subject>Apoptosis</subject><subject>Brain cancer</subject><subject>Confidence intervals</subject><subject>Infections</subject><subject>Ligands</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Original Research</subject><subject>PD-L1 protein</subject><subject>Systematic review</subject><subject>Tumors</subject><subject>Viral infections</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkc9rFTEQx4Mo9oeevMuCF0G2ZpJssrkIUrQWCj30eQ5xkn0vdTdZk13R_9689lmqpwyZz3xnvnwJeQX0jIFQ7683m7MbAKqAPyHHAKpvpeb06aP6iJyUckuplD0Tz8kRUx2XIMQx-X4ZMXtbvGvmnLbZTlMtnbfLrhnD1kbXQuN_zdmXElKskHcBl9LMKeW7kZhKKE2Izc7Pdknox3EdbW7QZgwxTbap38HHpbwgzwY7Fv_y8J6Sr58_bc6_tFfXF5fnH69a7BgsLfMeBvAoqWZIJQ4aee-4YBoHtMK5Dj2n3oEG6pxUHThhO9QgBUrlkJ-SD_e68_qtusG6O9vRzDlMNv82yQbzbyeGndmmn0ZoJTWoKvD2IJDTj9WXxUyh7I3Z6NNaDPTAek2Z7ir65j_0Nq05VnuGMcEUoz3fC767pzCnUrIfHo4BavYhmhqiOYRY6deP739g_6bG_wAdrpra</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Gu, Xiaobin</creator><creator>Gao, Xian-Shu</creator><creator>Xiong, Wei</creator><creator>Guo, Wei</creator><creator>Han, Linjun</creator><creator>Bai, Yun</creator><creator>Peng, Chuan</creator><creator>Cui, Ming</creator><creator>Xie, Mu</creator><general>Taylor &amp; Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients</title><author>Gu, Xiaobin ; Gao, Xian-Shu ; Xiong, Wei ; Guo, Wei ; Han, Linjun ; Bai, Yun ; Peng, Chuan ; Cui, Ming ; Xie, Mu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-2ee1f1ec6092c06cf9c38d3429cfca4dd5ce30ed1910dd6751d4a5c9164c67dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis</topic><topic>Brain cancer</topic><topic>Confidence intervals</topic><topic>Infections</topic><topic>Ligands</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Original Research</topic><topic>PD-L1 protein</topic><topic>Systematic review</topic><topic>Tumors</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Xiaobin</creatorcontrib><creatorcontrib>Gao, Xian-Shu</creatorcontrib><creatorcontrib>Xiong, Wei</creatorcontrib><creatorcontrib>Guo, Wei</creatorcontrib><creatorcontrib>Han, Linjun</creatorcontrib><creatorcontrib>Bai, Yun</creatorcontrib><creatorcontrib>Peng, Chuan</creatorcontrib><creatorcontrib>Cui, Ming</creatorcontrib><creatorcontrib>Xie, Mu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Xiaobin</au><au>Gao, Xian-Shu</au><au>Xiong, Wei</au><au>Guo, Wei</au><au>Han, Linjun</au><au>Bai, Yun</au><au>Peng, Chuan</au><au>Cui, Ming</au><au>Xie, Mu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>9</volume><spage>4805</spage><epage>4813</epage><pages>4805-4813</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Accumulating studies have investigated the prognostic and clinical significance of programmed death ligand-1 (PD-L1) expression in patients with hepatocellular carcinoma (HCC); however, the results were conflicting and inconclusive. We conducted a meta-analysis to combine controversial data to precisely evaluate this issue. Relevant studies were thoroughly searched on PubMed, Web of Science, and Embase until April 2016. Eligible studies were evaluated by selection criteria. Hazard ratio (HR) with 95% confidence interval (CI) was used to estimate the prognostic role of PD-L1 for overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS). Odds ratio (OR) with 95% CI were selected to assess the relationship between PD-L1 and clinicopathological features of HCC patients. Publication bias was tested using Begg's funnel plot. A total of seven studies published from 2009 to 2016 were included for meta-analysis. The data showed that high PD-L1 expression was correlated to shorter OS (HR =2.09, 95% CI: 1.66-2.64, P&lt;0.001) as well as poor DFS/RFS (HR =2.3, 95% CI: 1.46-3.62, P&lt;0.001). In addition, increased PD-L1 expression was also associated with tumor differentiation (HR =1.51, 95% CI: 1-2.29, P=0.05), vascular invasion (HR =2.16, 95% CI: 1.43-3.27, P&lt;0.001), and α-fetoprotein (AFP; HR =1.46, 95% CI: 1-2.14, P=0.05), but had no association with tumor stage, tumor size, hepatitis history, sex, age, or tumor multiplicity. No publication bias was found for all analyses. This meta-analysis revealed that overexpression of PD-L1 was predictive for shortened OS and DFS/RFS in HCC. Furthermore, increased PD-L1 expression was associated with less differentiation, vascular invasion, and AFP elevation.</abstract><cop>New Zealand</cop><pub>Taylor &amp; Francis Ltd</pub><pmid>27536144</pmid><doi>10.2147/OTT.S110713</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6930
ispartof OncoTargets and therapy, 2016-01, Vol.9, p.4805-4813
issn 1178-6930
1178-6930
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4976917
source Taylor & Francis (Open Access); Publicly Available Content Database; PubMed Central
subjects Apoptosis
Brain cancer
Confidence intervals
Infections
Ligands
Liver cancer
Medical prognosis
Meta-analysis
Original Research
PD-L1 protein
Systematic review
Tumors
Viral infections
title Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T04%3A23%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20programmed%20death%20ligand-1%20expression%20predicts%20poor%20prognosis%20in%20hepatocellular%20carcinoma%20patients&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Gu,%20Xiaobin&rft.date=2016-01-01&rft.volume=9&rft.spage=4805&rft.epage=4813&rft.pages=4805-4813&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S110713&rft_dat=%3Cproquest_pubme%3E2242720837%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c521t-2ee1f1ec6092c06cf9c38d3429cfca4dd5ce30ed1910dd6751d4a5c9164c67dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2242720837&rft_id=info:pmid/27536144&rfr_iscdi=true